Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 stud... von Passaro, A, Wang, J, Wang, Y, Lee, S-H, Melosky, B, Shih, J-Y, Wang, J, Azuma, K, Juan-Vidal, O, Cobo, M, Felip, E, Girard, N, Cortot, A B, Califano, R, Cappuzzo, F, Owen, S, Popat, S, Tan, J-L, Salinas, J, Tomasini, P, Gentzler, R D, William, Jr, W N, Reckamp, K L, Takahashi, T, Ganguly, S, Kowalski, D M, Bearz, A, MacKean, M, Barala, P, Bourla, A B, Girvin, A, Greger, J, Millington, D, Withelder, M, Xie, J, Sun, T, Shah, S, Diorio, B, Knoblauch, R E, Bauml, J M, Campelo, R G, Cho, B C

Volltext

PCR172 Patient-Reported Outcomes in Non-Small Cell Lung Cancer: Psychometric Evaluation of the PROMIS PF-SF 8C and NSCLC-SAQ in Phase 3 Clinical Trials von Houts, CR, Savord, A, Gardner, M, Mattera, M, Peipert, J, Agrawal, T, Baig, M, Barala, P, Bauml, J, Diorio, B, Girvin, A, Li, T, Sermon, J, Shah, S, Withelder, M, Wortman-Vayn, H, Schuchard, J

Volltext

1835P A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC) von Sandhu, S.K., Gotto, G., Vera-Badillo, F.E., Byun, S-S., Cutuli, H.J., Gomes, A.J.P.D.S., Helissey, C., Karsh, L.I., Peer, A., Preto, D.D., Pu, Y-S., Ravilla, R., Roubaud, G., Skoneczna, I.A., Kim, W., Espina, B., Withelder, M., Urtishak, K., Francis, P.S.J., Saad, F.

Volltext